BeiGene's Brukinsa wins CLL approval after topping Imbruvica in head-to-head trial

The FDA greenlit BeiGene’s Brukinsa for use in chronic lymphocytic lymphoma, an approval that should substantially expand the market for the drug in the US after it topped the current leading therapy in a trial.